Research1d ago0 views

SOCS1-based therapeutic peptides improve liver disease and metabolic dysfunction in obesity and diabetes.

SOCS1-based peptides just got a strong vote of confidence from new research out of Spain and Chile. Researchers tested a SOCS1-derived peptidomimetic (MiS1) in a mouse model of obesity and type 2 diabetes. The results? MiS1 improved liver health and tackled the nasty metabolic dysfunction that comes with these conditions.

Sci Rep

by Soto-Catalán M, Opazo-Ríos L, Espadas C et al.

“SOCS1-based therapeutic peptides improve liver disease and metabolic dysfunction in obesity and diabetes. Soto-Catalán M(#)(1), Opazo-Ríos L(#)(2), Espadas C(3), Romero-Cote M(3), Lázaro I(4), Moreno JA(5), Gómez-Guerrero C(3), Egido J(#)(6), Mas-Fontao S(#)(3). Author information: (1)Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Universidad Autónoma de Madrid, Madrid, Spain. smas@fjd.es. (2)Facultad de Ciencias de la Salud, Universidad de Las Américas, 4301099, Concepción-Talcahuano, Chile. (3)Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Universidad Autónoma de Madrid, Madrid, Spain. (4)Cardiovascular Risk and Nutrition Research Group, Epidemiology and Public Health Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. (5)Department of Cell Biology, Physiology and Immunology, Maimónides Biomedical Research Institute of Cordoba (IMIBIC), UGC Nephrology, Hospital Universitario Reina Sofía, University of Cordoba, Córdoba, Spain. (6)Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Universidad Autónoma de Madrid, Madrid, Spain. jegido@fjd.es. (#)Contributed equally Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a growing global health challenge, closely linked to obesity and type 2 diabetes mellitus. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is a key mediator of inflammation and metabolic dysregulation in liver disease. This study investigates the therapeutic potential of a SOCS1-derived peptidomimetic (MiS1) in a mouse model of MASLD using obese, type 2 diabetic BTBR ob/ob mice. A six-week treatment with MiS1 (10 μg/g/day) significantly reduced body weight, serum transaminase levels, hepatic steatosis, and hepatocellular ballooning compared to untreated controls. MiS1-treated mice exhibited decreased hepatic triglyceride content, notably in palmitic (C16:0) and palmitoleic (C16:1n-7) acids, along with downregulation of key lipogenic enzymes. Inflammatory signaling was also attenuated, with lower expression of pro-inflammatory cytokines and increased expression of CD163, a marker of M2 anti-inflammatory macrophages. In vitro, MiS1 directly inhibited insulin-induced STAT3 phosphorylation and suppressed lipogenic gene expression in murine hepatocytes. These results demonstrate that JAK/STAT pathway inhibition via MiS1 ameliorates key pathological features of MASLD by concurrently targeting hepatic lipid metabolism and inflammation, highlighting its potential as a novel therapeutic approach for patients with obesity and diabetes. © 2026. The Author(s). Conflict of interest statement: Declarations. Competing interests: MSC, LPR, SMF, JE and CGG are inventors on a patent application for SOCS peptidomimetics. The other authors declare no competing interests.”

Here's the bottom line: metabolic dysfunction-associated steatotic liver disease (MASLD) is a major problem for people with obesity and diabetes. The JAK/STAT pathway, which drives inflammation and metabolic chaos in the liver, is a big target. MiS1 was designed to inhibit this pathway. When researchers dosed obese, diabetic mice with MiS1 for six weeks, the changes were clear:

•

Lower body weight and reduced liver enzymes — classic markers of improved liver function

•

Less hepatic steatosis and hepatocellular ballooning (so, less fat accumulation and less cell damage in the liver)

•

Hepatic triglycerides dropped, especially for the notorious palmitic (C16:0) and palmitoleic (C16:1n-7) acids

•

Lipogenic enzymes went down, indicating a real shift in liver metabolism

•

Inflammation markers dropped, and anti-inflammatory macrophage markers (CD163) rose

The peptide also blocked insulin-induced STAT3 phosphorylation and suppressed lipogenic genes in mouse liver cells. That's direct evidence of its mechanism—hitting both metabolic and inflammatory pathways at the molecular level.

Key takeaway: SOCS1-based peptides like MiS1 could open new doors for studying metabolic disease and liver health, especially in the context of obesity and diabetes. The JAK/STAT pathway is a hot target, and peptidomimetics are proving they can deliver real results in preclinical research.

Curious about the whole field of peptide-based metabolic research? Check out the peptide research index for more. Peptide science is just getting started—expect a lot more action here soon.

Back to News Read original on Sci Rep

SOCS1-based therapeutic peptides improve liver disease and metabolic dysfunction in obesity and diabetes.

Related Reading

Eu(3+)-mediated dual-crosslinked collagen-mimetic peptide/sodium alginate hydrogel for 3D-printed skin wound dressings.

Antimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide.

Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.